During this webinar, PwC’s Health Research Institute will review findings from a new global survey of industry executives, and provide analysis and commentary on key drug pricing issues.
Execs at this year's J.P. Morgan Healthcare Conference agreed the tone was somewhere between gloom and sunshine.
The stagnant pharma M&A scene will turn around in 2019, especially with recent declines in biotech valuations, experts predict.
Yes, next year may be a "a year of uncertainty," PwC says. But it's also a year of "opportunity" for pharma.
Blockbuster drug launches have strained health systems budgets in recent years by driving sizable spending hikes. But that trend may be nearing a lull, a new PwC report says.